Ireland-based brand-name and generics maker Endo announced on 18 May 2015 that it will acquire US-based Par Pharmaceutical Holdings (Par) from private equity firm TPG for US$8.05 billion. The deal, according to Endo and Par, will make them one of the top five generics companies in the US.

The deal will add Par’s portfolio of almost 100 generics to Endo’s rapidly expanding generics business. Par’s products include multiple dosage forms and delivery systems, including oral solids, oral suspensions, injectables and high barrier-to-entry products. Par’s portfolio also includes more than 200 abbreviated new drug applications (ANDAs), 115 of which have already been filed with the US Food and Drug Administration. Around 66 of these ANDAs are potential first-to-file generics, which would give 180 days of marketing exclusivity in the US.

Meanwhile, on 21 May 2015, India-based Strides announced that it had signed definitive agreements with certain wholly-owned subsidiaries of South Africa-based Aspen Pharmacare Holdings (Aspen) to acquire the company’s Australian generics business together with certain brand-name drugs.

This acquisition is expected to place Strides among the top three generics makers and among the top 10 pharma companies in Australia. The new business will operate under the Arrow Pharmaceuticals brand and will include around 140 generics and an extensive range of non-prescription pharmacy products. The divestment by Aspen forms part of the company’s decision to focus attention in areas ‘where most value can be added and to lessen complexity’.

Related articles
Strides and Shasun merger aims to spread risk

Endo to buy generics maker DAVA

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.